Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART-138 in Relapsed/Refractory Multiple Myeloma
NCT01886976Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2013
- Primary completion
- Jun 2016
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of CART-138 in multiple myeloma (MM), sponsored by Chinese PLA General Hospital. Primary endpoints: Occurrence of study related adverse events and Duration of in vivo survival of CART-138 cells up to 2 years. Status: unknown.
02
Drugs
CART-138
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01886976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01886976.